Canadian Hemophilia Society & Pfizer Care Until Research Program

The CHS / Pfizer Care Until Cure Research Program was established in the year 2000 in collaboration with Wyeth Canada, now Pfizer. Pfizer Canada strives every day to help Canadians live healthy, balanced lives. They do that by discovering and developing innovative medicines. As a company, they’re dedicated to building healthier communities and empowering Canadians to make healthier choices every day. At Pfizer Canada, they believe that to be truly healthy, it takes more than medication.

This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder.

Eligibility

Applicants must be Canadian citizens or permanent residents and affiliated with a Canadian university or not-for-profit health-related organization. Grants will be made available for clinical research, including outcome evaluation, in fields relevant to improving the quality of life of:

• persons with hemophilia
• persons with von Willebrand disease or other inherited bleeding disorders
• persons with related conditions such as HIV or hepatitis C infection
• carriers of an inherited bleeding disorder.

For the 2022-2023 granting period of the program, specific areas of interest have been identified and investigators are encouraged to submit proposals within these areas. The grants review committee will allocate funding to the strongest and most relevant projects included but not limited to the areas of interest listed below.

2022-2023 AREAS OF INTEREST include and are not limited to:

• Hemophilia A or B
• Clinical monitoring of hemophilia treatment
• Basic Science of Gene Therapy for Hemophilia
• Basic Science of TFPI & Anti-TFPI Monoclonal Antibodies
• Antifibrinolytic Therapy

Deadline: December 10, 2021

See Full Eligibility & Application Details